Franklin Genomic Advancements ETF (HELX) Research

This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.

Market snapshot

Symbol
HELX
Price
$36.04
Day change
0.00%
Market cap
$17.9M
52-week range
26.991-38.17
Sector
Financial Services
Industry
Asset Management

Peer companies

  • Brendan Wood TopGun ETF (BWTG)
  • Principal Real Estate Active Opportunities ETF (BYRE)
  • VanEck Digital India ETF (DGIN)
  • The Free Markets ETF (FMKT)
  • Horizon Kinetics Medical ETF (MEDX)
  • Global X - Nasdaq 100 Risk Managed Income ETF (QRMI)
  • RH Tactical Rotation ETF (RHRX)
  • Rainwater Equity ETF (RW)

Recent insider activity

  • TRANSIER WILLIAM L — A-Award (1843 shares) on 2006-07-03
  • DUROC-DANNER BERNARD J — A-Award (1340 shares) on 2006-07-03
  • FERRON MARTIN R — M-Exempt (5655 shares) on 2006-05-25
  • FERRON MARTIN R — M-Exempt (5655 shares) on 2006-05-25
  • TRIPODO ANTHONY — M-Exempt (15000 shares) on 2006-04-05

Open Franklin Genomic Advancements ETF (HELX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.